MX2017013859A - Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. - Google Patents
Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña.Info
- Publication number
- MX2017013859A MX2017013859A MX2017013859A MX2017013859A MX2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapies
- limited
- integrin
- small molecule
- methods
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 5
- 108010044426 integrins Proteins 0.000 title abstract 5
- 239000003446 ligand Substances 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003384 small molecules Chemical class 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000001815 biotherapy Methods 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 230000008611 intercellular interaction Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000581 natural killer T-cell Anatomy 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960000575 trastuzumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Los mimóticos del ligando de integrina de molócula pequeña facilitan las interacciones del ligando de integrina, los cuales se pueden utilizar para preparar vacunas, terapias de cólulas adoptivas, inmunoterapias para el cáncer, y una variedad de otras condiciones. Ya que las interacciones de cólula-cólula mediadas por integrina son decisivas para la presentación de antígenos y el exterminio de cólulas efectoras, aumentar la eficiencia de las interacciones de ligando receptor de integrina estabilizará la sinapsis inmunitaria y mejorará las funciones efectoras. Las composiciones y métodos que incluyen los mimóticos mejoran: (1) el cebado de vacunas (incluyendo, de manera enunciativa, vacunas contra el cáncer); (2) la actividad citolítica de las terapias con cólulas adoptivas (incluyendo, de manera enunciativa, cólulas YdT, CTL, NK, iNKT); (3) las inmunoterapias (incluyendo, de manera enunciativa, estrategias de bloqueo para punto de comprobación negativo tales como anti-CTLA-4 y anti-PD-1); y (4) las terapias biológicas (incluyendo, de manera enunciativa, trastuzumab y rituxamab), con los cuales el mecanismo de acción incluye una citotoxicidad celular dependiente de anticuerpos (ADCC).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154554P | 2015-04-29 | 2015-04-29 | |
| PCT/US2016/029683 WO2016176400A2 (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
| US15/140,711 US10342866B2 (en) | 2015-04-29 | 2016-04-28 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013859A true MX2017013859A (es) | 2018-07-06 |
Family
ID=57198770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013859A MX2017013859A (es) | 2015-04-29 | 2016-04-28 | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. |
| MX2024002456A MX2024002456A (es) | 2015-04-29 | 2017-10-27 | Composiciones novedosas y métodos para inmunoterapias que comprenden adyuvantes del agonista del ligando receptor de integrina de molécula pequeña. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002456A MX2024002456A (es) | 2015-04-29 | 2017-10-27 | Composiciones novedosas y métodos para inmunoterapias que comprenden adyuvantes del agonista del ligando receptor de integrina de molécula pequeña. |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10342866B2 (es) |
| JP (2) | JP2018514562A (es) |
| KR (3) | KR20240052078A (es) |
| CN (1) | CN107820429B (es) |
| AU (1) | AU2016254034B2 (es) |
| CA (1) | CA2984316A1 (es) |
| IL (1) | IL255297B (es) |
| MX (2) | MX2017013859A (es) |
| SG (2) | SG11201708846XA (es) |
| WO (1) | WO2016176400A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311619B2 (en) * | 2016-04-28 | 2022-04-26 | 7 Hills Pharma Inc. and Texas Heart Institute | Integrin activator vaccine compositions |
| MX2017013859A (es) * | 2015-04-29 | 2018-07-06 | 7 Hills Interests Llc | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. |
| WO2017165778A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2018112364A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| WO2018112360A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| AU2020332310A1 (en) * | 2019-08-16 | 2022-03-10 | The Regents Of The University Of California | Combined cancer therapy involving chemical activation of integrins and targeted cell immunotherapy |
| US12109263B2 (en) * | 2020-09-10 | 2024-10-08 | 7 Hills Pharma LLC | Integrin agonists or activating compounds and methods for making and using same |
| EP4384516A4 (en) * | 2021-08-10 | 2025-08-06 | Texas Heart Inst | AMINOARYL-INTEGRIN AGONIST COMPOUNDS |
| WO2023215314A1 (en) * | 2022-05-03 | 2023-11-09 | 7 Hills Pharma LLC | Novel lipid-based small molecule integrin receptor-ligand agonist adjuvants carrier compositions, integrin agonist adjuvant pharmaceutical compositions therefrom, and methods for making and using same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1461336B1 (en) | 2001-12-20 | 2013-05-22 | CHIESI FARMACEUTICI S.p.A. | 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| ZA200610158B (en) * | 2004-06-04 | 2008-07-30 | Genentech Inc | Method for treating multiple sclerosis |
| CN101227885A (zh) | 2005-07-26 | 2008-07-23 | 株式会社资生堂 | 皱纹防止·改善剂 |
| WO2009000406A1 (en) * | 2007-06-22 | 2008-12-31 | Bayer Healthcare Ag | Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease |
| US10369204B2 (en) * | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| CN102803237B (zh) * | 2009-06-12 | 2014-09-24 | 埃科特莱茵药品有限公司 | 作为alx受体激动剂的噁唑和噻唑衍生物 |
| US9023876B2 (en) | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| EP3388429A1 (en) * | 2010-11-16 | 2018-10-17 | Texas Heart Institute | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
| US20150250883A1 (en) | 2014-02-12 | 2015-09-10 | 7 Hills Pharma, Llc | Compositions and methods to improve the homing and grafting of hematopoetic stem cells |
| EP3164127A4 (en) | 2014-07-01 | 2017-11-22 | 7 Hills Interests, Llc | Compositions and methods to improve adoptive cell therapies |
| MX2017013859A (es) * | 2015-04-29 | 2018-07-06 | 7 Hills Interests Llc | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. |
-
2016
- 2016-04-28 MX MX2017013859A patent/MX2017013859A/es unknown
- 2016-04-28 CN CN201680036891.3A patent/CN107820429B/zh active Active
- 2016-04-28 WO PCT/US2016/029683 patent/WO2016176400A2/en not_active Ceased
- 2016-04-28 KR KR1020247011631A patent/KR20240052078A/ko active Pending
- 2016-04-28 CA CA2984316A patent/CA2984316A1/en active Pending
- 2016-04-28 SG SG11201708846XA patent/SG11201708846XA/en unknown
- 2016-04-28 SG SG10201911607YA patent/SG10201911607YA/en unknown
- 2016-04-28 KR KR1020247011632A patent/KR20240052079A/ko active Pending
- 2016-04-28 US US15/140,711 patent/US10342866B2/en active Active
- 2016-04-28 JP JP2017556837A patent/JP2018514562A/ja active Pending
- 2016-04-28 KR KR1020177034574A patent/KR20170136651A/ko not_active Ceased
- 2016-04-28 AU AU2016254034A patent/AU2016254034B2/en active Active
-
2017
- 2017-10-27 IL IL255297A patent/IL255297B/en unknown
- 2017-10-27 MX MX2024002456A patent/MX2024002456A/es unknown
-
2019
- 2019-04-25 US US16/394,270 patent/US10709780B2/en active Active
- 2019-04-25 US US16/394,277 patent/US10716849B2/en active Active
- 2019-07-19 US US16/516,907 patent/US10709781B2/en active Active
-
2021
- 2021-05-06 JP JP2021078488A patent/JP7244570B2/ja active Active
- 2021-06-29 US US17/362,512 patent/US12201686B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220001009A1 (en) | 2022-01-06 |
| US10342866B2 (en) | 2019-07-09 |
| KR20170136651A (ko) | 2017-12-11 |
| WO2016176400A2 (en) | 2016-11-03 |
| US20190343952A1 (en) | 2019-11-14 |
| KR20240052078A (ko) | 2024-04-22 |
| KR20240052079A (ko) | 2024-04-22 |
| SG10201911607YA (en) | 2020-01-30 |
| US10716849B2 (en) | 2020-07-21 |
| AU2016254034B2 (en) | 2021-11-04 |
| SG11201708846XA (en) | 2017-11-29 |
| US10709781B2 (en) | 2020-07-14 |
| US20200054743A1 (en) | 2020-02-20 |
| JP2018514562A (ja) | 2018-06-07 |
| JP2021121602A (ja) | 2021-08-26 |
| US20160339098A1 (en) | 2016-11-24 |
| CA2984316A1 (en) | 2016-11-03 |
| CN107820429A (zh) | 2018-03-20 |
| CN107820429A8 (zh) | 2018-06-01 |
| IL255297A0 (en) | 2017-12-31 |
| CN107820429B (zh) | 2022-08-16 |
| US20190351052A1 (en) | 2019-11-21 |
| MX2024002456A (es) | 2024-03-08 |
| AU2016254034A1 (en) | 2017-12-14 |
| WO2016176400A3 (en) | 2016-12-08 |
| JP7244570B2 (ja) | 2023-03-22 |
| IL255297B (en) | 2021-10-31 |
| US12201686B2 (en) | 2025-01-21 |
| US10709780B2 (en) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013859A (es) | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. | |
| MX2024002644A (es) | Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales. | |
| MX2019014008A (es) | Composiciones y usos para inmunoterapia. | |
| BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
| CL2019000326A1 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos | |
| MX2022012082A (es) | Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva. | |
| AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| BR112017008710A8 (pt) | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva | |
| CO2018011804A2 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos | |
| CL2018002828A1 (es) | Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores. | |
| MX2022009849A (es) | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. | |
| NI201700001A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| AR105433A1 (es) | Métodos para mejorar la eficacia y expansión de las células inmunes | |
| PE20181075A1 (es) | Nuevos pepticos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia linfocitica cronica (llc) y otros tipos de cancer | |
| BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
| MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| MX389160B (es) | Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas. | |
| MX2015004287A (es) | Composiciones y metodos para inmunoterapia. | |
| MX2020004094A (es) | Metodos para administrar inmunoterapia con receptores de antigeno quimerico. | |
| MX2021013368A (es) | Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno. | |
| MX2020001358A (es) | Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso. | |
| MX2021002702A (es) | Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas. | |
| MX2018004121A (es) | Receptores de antigeno y usos de los mismos. | |
| CO2020006855A2 (es) | Composiciones y métodos para el agotamiento de células cd2+ | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. |